Pharming Group announced that the U.S. Food and Drug Administration (FDA) has issued a Complete Response Letter (CRL) regarding its supplemental New Drug Application (sNDA) for Joenja® (leniolisib) intended for children aged 4 to 11 years with Activated Phosphoinositide 3-Kinase Delta Syndrome (APDS). The CRL indicates that the FDA has not yet approved the application and has provided additional information or requirements that must be addressed.
The company will review the FDA’s feedback and determine the next steps to respond to the CRL and advance the approval process for this pediatric indication.
**Why this matters**
Joenja® is already approved for treating APDS in older patients, and expanding its use to younger children could provide an important treatment option for this rare immune disorder. The FDA’s response highlights the ongoing regulatory scrutiny required to ensure safety and efficacy in pediatric populations.
Source: NewsData